Modality
ADC
MOA
STINGag
Target
BET
Pathway
Tau
DMD
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
Jul 2017
→ Nov 2030
Phase 3Current
NCT07587815
775 pts·DMD
2017-07→2028-10·Terminated
NCT06560504
244 pts·DMD
2024-05→2030-11·Terminated
1,019 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-10-022.5y awayPh3 Readout· DMD
2030-11-034.6y awayPh3 Readout· DMD
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2028-10-02 · 2.5y away
DMD
Ph3 Readout
2030-11-03 · 4.6y away
DMD
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07587815 | Phase 3 | DMD | Terminated | 775 | DAS28 |
| NCT06560504 | Phase 3 | DMD | Terminated | 244 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-5389 | Roche | Preclinical | RET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 |